Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.8231
-0.0069 (-0.83%)
At close: Jan 14, 2026, 4:00 PM EST
0.8442
+0.0211 (2.56%)
After-hours: Jan 14, 2026, 6:04 PM EST
Galmed Pharmaceuticals Employees
As of December 31, 2024, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,450,000
Market Cap
4.51M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | -2 | -25.00% |
| Dec 31, 2023 | 8 | -2 | -20.00% |
| Dec 31, 2022 | 10 | -14 | -58.33% |
| Dec 31, 2021 | 24 | 0 | - |
| Dec 31, 2020 | 24 | 3 | 14.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GLMD News
- 5 weeks ago - Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PRNewsWire
- 5 weeks ago - Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PRNewsWire
- 6 weeks ago - Galmed Issues CEO Letter to Shareholders - PRNewsWire
- 7 weeks ago - Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 2 months ago - Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine - PRNewsWire
- 2 months ago - Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro - PRNewsWire
- 4 months ago - Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 5 months ago - Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value - PRNewsWire